
Stealthy Auris Surgical Robotics raises $34M for eye-surgery device
April 1, 2014 by Brad Perriello

Stealthy Auris Surgical Robotics, which is led by Intuitive Surgical founder Dr. Frederic Moll, said it raised more than $34 million in an equity round.
Redwood City, Calif.-based Auris is developing a surgical robot for ophthalmological procedures. Although Auris did not reveal the names of the 20 backers who joined the $34.4 million round, it listed several venture capital investors as directors in a regulatory filing. Read more
Axonics raises $33M for its neuromodulation tech
March 28, 2014 by Brad Perriello


Axonics Modulation Technologies said it drummed up a $32.6 million Series A round for the neuromodulation technology it’s developing to treat chronic pain and overactive bladder.
Irvine, Calif.-based Axonics said the round was led by Edmond de Rothschild Investment Partners and included NeoMed Management, Legend Capital and "a select group of private individuals." Read more
Cytomedix lands $35M for wound care products
April 2, 2014 by Arezu Sarvestani


Wound care therapies maker Cytomedix landed a $35 million investment commitment from Deerfield Management Co., to be handed down in 2 tranches.
Deerfield has already invested $9 million, and will deliver an additional $26 million pending shareholder approval to issue additional shares of Cytomedix stock, according to a press release. Deerfield’s investment is tied to purchases of senior secured convertible debt facility with warrants. Read more
Transcend Medical closes on $22M Series C round
April 2, 2014 by Brad Perriello


Transcend Medical said it closed on a Series C round worth $22 million that included a contribution from an unnamed "global pharmaceutical and medical device company."
Transcend, which is developing a micro-stent called the CyPass to treat glaucoma, said it plans to use the proceeds to complete its Compass pivotal trial for the CyPass device. The study’s follow-up period is slated to be complete during the 2nd quarter of 2015, according to a press release. Read more
Halt Medical raises $92.8M ahead of U.S. launch of uterine fibroid treatment
April 3, 2014 by Arezu Sarvestani


California women’s health company Halt Medical is raising capital ahead of a major commercial bid for its Acessa radiofrequency-based uterine fibroid treatment.
The company this week listed more than $92.8 million raised in a pair of funding rounds, with another $9.5 million left to close the larger of the 2. Halt plans to use the funds to restructure some existing debt and fund U.S. commercial efforts, CEO Jeffrey Cohen told MassDevice.com. Read more